Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2024 Filed Apr 16, 2025 23:07 UTC |
Maraoui ClaudeDirector · President & CEO
|
GrantCommon Stock, $0.0001 par value | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035599 · tm2512519-2_4seq1.xml · nonDerivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,353,147 F2 · shares: On May 1, 2024, the reporting person was granted 175,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 58,333 shares on May 1, 2025, 58,333 shares on May 1, 2026 and 58,334 shares on May 1, 2027. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Due to administrative error, the above transactions are being reported late. The aggregate amount of securities beneficially owned includes the delinquent transactions plus all transactions reported in Form 4s filed after the date of the delinquent transactions. Read SEC document |
| May 01, 2024 Filed Apr 16, 2025 23:06 UTC | GrantCommon Stock, $0.0001 par value | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035598 · tm2512519-1_4seq1.xml · nonDerivative · entry 2 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,966 F2 · shares: On May 1, 2024, the reporting person was granted 80,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 26,666 shares on May 1, 2025, 26,667 shares on May 1, 2026 and 26,667 shares on May 1, 2027. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Due to administrative error, the above transactions are being reported late. The aggregate amount of securities beneficially owned includes the delinquent transactions plus all transactions reported in Form 4s filed after the date of the delinquent transactions. Read SEC document |
|
| March 25, 2024 Filed Mar 27, 2024 11:00 UTC |
ROSENWALD LINDSAY A MDDirector
|
PurchaseCommon Stock, $0.0001 par value | 10,000 | $3.04 | $30,400.00 |
DisclosureSEC source: 0001104659-24-039354 · tm249895-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,245 F1 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 20:02 UTC |
Smith Justin AdamDirector
|
PurchaseCommon Stock, $0.0001 par value | 30,000 | $3.47 | $104,100.00 |
DisclosureSEC source: 0001104659-24-038433 · tm249705-2_4seq1.xml · nonDerivative · entry 1 Smith Justin Adam · CIK 0001894583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,717 F1 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 20:01 UTC |
ROSENWALD LINDSAY A MDDirector
|
PurchaseCommon Stock, $0.0001 par value | 20,000 | $3.40 | $68,000.00 |
DisclosureSEC source: 0001104659-24-038431 · tm249705-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,245 F1 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 20:03 UTC |
Maraoui ClaudeDirector · President & CEO
|
PurchaseCommon Stock, $0.0001 par value | 10,000 | $3.48 | $34,790.00 |
DisclosureSEC source: 0001104659-24-038437 · tm249705-3_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,163,430 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 22, 2024, was $3.41 to $3.48. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:54 UTC |
Benesch JosephInterim CFO
|
SaleCommon Stock, $0.0001 par value | 2,450 | $3.75 | $9,187.50 |
DisclosureSEC source: 0001104659-24-027147 · tm247166-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,710 F1 · shares: In connection with the vesting of restricted stock units on February 20, 2024, a total of 2,768 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 22, 2024, was $3.73 to $3.78. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| January 03, 2024 Filed Apr 16, 2025 23:07 UTC |
Maraoui ClaudeDirector · President & CEO
|
GrantCommon Stock, $0.0001 par value | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035599 · tm2512519-2_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,178,147 F1 · shares: On January 3, 2024, the reporting person was granted 175,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that vested or will vest in accordance with the following schedule: 58,333 shares on July 3, 2024, 58,333 shares on July 3, 2025 and 58,334 shares on July 3, 2026. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Due to administrative error, the above transactions are being reported late. The aggregate amount of securities beneficially owned includes the delinquent transactions plus all transactions reported in Form 4s filed after the date of the delinquent transactions. Read SEC document |
| January 03, 2024 Filed Apr 16, 2025 23:06 UTC | GrantCommon Stock, $0.0001 par value | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035598 · tm2512519-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,966 F1 · shares: On January 3, 2024, the reporting person was granted 80,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that vested or will vest in accordance with the following schedule: 26,666 shares on July 3, 2024, 26,667 shares on July 3, 2025 and 26,667 shares on July 3, 2026. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Due to administrative error, the above transactions are being reported late. The aggregate amount of securities beneficially owned includes the delinquent transactions plus all transactions reported in Form 4s filed after the date of the delinquent transactions. Read SEC document |
|
| November 28, 2023 Filed Nov 29, 2023 16:42 UTC |
Paley JeffreyDirector
|
SaleCommon Stock, par value $0.0001 per share | 1,745 | $5.22 | $9,108.90 |
DisclosureSEC source: 0001104659-23-122072 · tm2331786-1_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,727 Read SEC document |
| November 08, 2023 Filed Dec 8, 2023 17:01 UTC |
Paley JeffreyDirector
|
SaleCommon Stock, par value $0.0001 per share | 255 | $3.76 | $958.80 |
DisclosureSEC source: 0001104659-23-124743 · tm2332498-1_4seq1.xml · nonDerivative · entry 2 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,217 F1 · balance_after: The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024. Read SEC document |
| November 07, 2023 Filed Dec 8, 2023 17:01 UTC |
Paley JeffreyDirector
|
SaleCommon Stock, par value $0.0001 per share | 2,245 | $3.48 | $7,812.60 |
DisclosureSEC source: 0001104659-23-124743 · tm2332498-1_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,472 F1 · balance_after: The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 20:01 UTC |
Smith Justin AdamDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 33,000 | $2.98 | $98,340.00 |
DisclosureSEC source: 0001104659-23-109604 · tm2328591-1_4seq1.xml · nonDerivative · entry 1 Smith Justin Adam · CIK 0001894583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,717 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 13, 2023, was $2.80 to $3.00. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2023 Filed Oct 10, 2023 16:41 UTC |
Paley JeffreyDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 15,000 | $2.98 | $44,700.00 |
DisclosureSEC source: 0001104659-23-108323 · tm2328171-1_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,472 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 6, 2023, was $2.97 to $2.99. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 16:01 UTC |
Paley JeffreyDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 30,000 | $2.97 | $89,100.00 |
DisclosureSEC source: 0001104659-23-103509 · tm2326865-1_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,472 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 21, 2023, was $2.82 to $3.00. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 17:25 UTC |
ROSENWALD LINDSAY A MDDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $2.23 | $223,000.00 |
DisclosureSEC source: 0001104659-23-099229 · tm2325760-1_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,245 F1 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 17:26 UTC |
Maraoui ClaudeDirector · President & CEO
|
PurchaseCommon Stock, par value $0.0001 per share | 26,044 | $2.52 | $65,630.88 |
DisclosureSEC source: 0001104659-23-099230 · tm2325760-2_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,153,430 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 6, 2023, was $2.11 to $2.60. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:05 UTC |
Benesch JosephSee Remarks
|
SaleCommon Stock, par value $0.0001 per share | 4,072 | $1.76 | $7,166.72 |
DisclosureSEC source: 0001104659-23-083825 · tm2322027-2_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,160 F1 · shares: In connection with the vesting of restricted stock units on July 24, 2023, a total of 4,072 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 24, 2023, was $1.76 to $1.80. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:05 UTC |
Maraoui ClaudeDirector · President & CEO
|
SaleCommon Stock, par value $0.0001 per share | 20,767 | $1.76 | $36,549.92 |
DisclosureSEC source: 0001104659-23-083828 · tm2322027-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,127,386 F1 · shares: In connection with the vesting of restricted stock units on July 24, 2023, a total of 20,767 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on July 24, 2023, was $1.76 to $1.80. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 20:06 UTC |
Smith Justin AdamDirector
|
GrantCommon Stock, par value $0.0001 per share | 27,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083833 · tm2321950-3_4seq1.xml · nonDerivative · entry 1 Smith Justin Adam · CIK 0001894583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,717 F1 · shares: On July 21, 2023, the reporting person was granted 27,472 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2024. F2 · balance_after: Includes 61,717 restricted stock units, 27,472 units of which will vest in full on July 21, 2024 as set forth in footnote 1, and 10,000 of which will vest on July 1, 2024. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 20:06 UTC |
Toledano Miranda JayneDirector
|
GrantCommon Stock, par value $0.0001 per share | 27,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083831 · tm2321950-4_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,717 F1 · shares: On July 21, 2023, the reporting person was granted 27,472 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2024. F2 · balance_after: Includes 61,717 restricted stock units, 27,472 of which will vest in full on July 21, 2024 as set forth in footnote 1, and 10,000 units of which will vest on July 1, 2024. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 20:07 UTC |
Herskowitz NeilDirector
|
GrantCommon Stock, par value $0.0001 per share | 27,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083836 · tm2321950-1_4seq1.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,717 F1 · shares: On July 21, 2023, the reporting person was granted 27,472 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2024. F2 · balance_after: Includes 61,717 restricted stock units, 27,472 of which will vest in full on July 21, 2024 as set forth in footnote 1, and 10,000 units of which will vest on July 1, 2024. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 16:06 UTC |
Paley JeffreyDirector
|
GrantCommon Stock, par value $0.0001 per share | 27,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083834 · tm2321950-2_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,717 F1 · shares: On July 21, 2023, the reporting person was granted 27,472 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2024. F2 · balance_after: Includes 61,717 restricted stock units, 27,472 units of which will vest in full on July 21, 2024 as set forth in footnote 1, and 10,000 units of which will vest on July 1, 2024. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:31 UTC |
Maraoui ClaudeDirector · President & CEO
|
SaleCommon Stock, par value $0.0001 per share | 24,377 | $1.34 | $32,665.18 |
DisclosureSEC source: 0001104659-23-062286 · tm2316163-1_4seq1.xml · nonDerivative · entry 2 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,148,153 F1 · shares: In connection with the vesting of restricted stock units on May 16, 2023, a total of 44,377 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F4 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on May 17, 2023 was $1.20 to $1.40. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:31 UTC |
Maraoui ClaudeDirector · President & CEO
|
SaleCommon Stock, par value $0.0001 per share | 20,000 | $1.25 | $25,000.00 |
DisclosureSEC source: 0001104659-23-062286 · tm2316163-1_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,172,530 F1 · shares: In connection with the vesting of restricted stock units on May 16, 2023, a total of 44,377 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on May 16, 2023 was $1.25 to $1.27. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| May 12, 2023 Filed May 31, 2024 22:26 UTC |
Fortress Biotech, Inc.10% owner
|
OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 5 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,860,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 22:01 UTC |
Benesch JosephInterim CFO
|
SaleCommon Stock, par value $0.0001 per share | 2,768 | $1.97 | $5,452.96 |
DisclosureSEC source: 0001104659-23-024810 · tm237632-1_4seq1.xml · nonDerivative · entry 1 Benesch Joseph · CIK 0001887515 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,232 F1 · shares: In connection with the vesting of shares on February 20, 2023, a total of 2,768 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on February 21, 2023, was $1.95 to $1.98. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| February 12, 2023 Filed May 31, 2024 22:26 UTC |
Fortress Biotech, Inc.10% owner
|
OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 4 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,910,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| November 12, 2022 Filed May 31, 2024 22:26 UTC |
Fortress Biotech, Inc.10% owner
|
OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 3 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,960,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:30 UTC |
De Paolantonio Ernest RobertChief Financial Officer
|
SaleCommon Stock, par value $0.0001 per share | 10,093 | $2.41 | $24,324.13 |
DisclosureSEC source: 0001104659-22-106787 · tm2227683-1_4seq1.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,907 F1 · shares: In connection with the vesting of 40,000 shares on October 1, 2022, a total of 10,093 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 4, 2022, was $2.38 to $2.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| October 04, 2022 Filed Mar 1, 2023 21:46 UTC Amendment |
De Paolantonio Ernest RobertSee Remarks
|
SaleCommon Stock, par value $0.0001 per share | 10,093 | $2.41 | $24,324.13 |
DisclosureSEC source: 0001104659-23-027555 · tm237728-1_4aseq1.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,907 F1 · shares: In connection with the vesting of 40,000 shares on October 1, 2022, a total of 10,093 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F3 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 4, 2022, was $2.38 to $2.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · acquired: Due to a clerical error, the original Form 4 filed on October 6, 2022 reflected an acquisition of 10,029 shares in lieu of a disposition of 10,029 shares. The amount of securities beneficially owned following the reported transaction reported in the previously filed Form 4 is correct. F4 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| August 12, 2022 Filed May 31, 2024 22:26 UTC |
Fortress Biotech, Inc.10% owner
|
OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 2 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,010,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 13:39 UTC |
Smith Justin AdamDirector
|
GrantCommon Stock, par value $0.0001 per share | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082290 · tm2221508-6_4seq1.xml · nonDerivative · entry 1 Smith Justin Adam · CIK 0001894583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,245 F1 · shares: On July 21, 2022, the reporting person was granted 14,245 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2023. F2 · balance_after: Includes 34,245 restricted stock units, 14,245 of which will vest as set forth in footnote 1, and 20,000 of which will vest in increments as follows: (1) 10,000 units on July 1, 2023, and (2) 10,000 units on July 1, 2024. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 13:40 UTC |
ROSENWALD LINDSAY A MDDirector
|
GrantCommon Stock, par value $0.0001 per share | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082291 · tm2221508-7_4seq1.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,245 F1 · shares: On July 21, 2022, the reporting person was granted 14,245 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2023. F2 · balance_after: Includes 14,245 restricted stock units, which will vest as set forth in footnote 1. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 13:35 UTC |
Toledano Miranda JayneDirector
|
GrantCommon Stock, par value $0.0001 per share | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082287 · tm2221508-3_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,245 F1 · shares: On July 21, 2022, the reporting person was granted 14,245 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2023. F2 · balance_after: Includes 34,245 restricted stock units, 14,245 of which will vest as set forth in footnote 1, and 20,000 of which will vest in increments as follows: (1) 10,000 units on July 1, 2023, and (2) 10,000 units on July 1, 2024. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 13:36 UTC |
Herskowitz NeilDirector
|
GrantCommon Stock, par value $0.0001 per share | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082288 · tm2221508-4_4seq1.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,245 F1 · shares: On July 21, 2022, the reporting person was granted 14,245 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2023. F2 · balance_after: Includes 34,245 restricted stock units, 14,245 of which will vest over various time periods as set forth in footnote 1, and 20,000 of which will vest in increments as follows: (1) 10,000 units on July 1, 2023, and (2) 10,000 units on July 1, 2024. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 09:32 UTC |
De Paolantonio Ernest RobertChief Financial Officer
|
GrantCommon Stock, par value $0.0001 per share | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082285 · tm2221508-1_4seq1.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 F1 · shares: On July 21, 2022, the reporting person was granted 150,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan. One-fourth of the shares will vest on each of July 21, 2023, 2024, 2025 and 2026, subject to the reporting person's continuous service with the Issuer. F2 · balance_after: Includes restricted stock units, 150,000 of which will vest over various time periods as set forth in footnote 1, and 120,000 of which will vest in three increments as follows: (1) 40,000 units on October 1, 2022, (2) 40,000 units on October 1, 2023, and (3) 40,000 units on October 1, 2024. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 09:38 UTC |
Paley JeffreyDirector
|
GrantCommon Stock, par value $0.0001 per share | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082289 · tm2221508-5_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,245 F1 · shares: On July 21, 2022, the reporting person was granted 14,245 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2023. F2 · balance_after: Includes 34,245 restricted stock units, 14,245 of which will vest as set forth in footnote 1, and 20,000 of which will vest in increments as follows: (1) 10,000 units on July 1, 2023, and (2) 10,000 units on July 1, 2024. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 13:34 UTC |
Maraoui ClaudeDirector · President & CEO
|
GrantCommon Stock, par value $0.0001 per share | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082286 · tm2221508-2_4seq1.xml · nonDerivative · entry 1 Maraoui Claude · CIK 0001893880 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,192,530 F1 · shares: On July 21, 2022, the reporting person was granted 300,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan. One-fourth of the shares will vest on each of July 21, 2023, 2024, 2025 and 2026, subject to the reporting person's continuous service with the Issuer. F2 · balance_after: Includes 742,530 restricted stock units, 300,000 of which will vest over various time periods as set forth in footnote 1, and 442,530 of which will vest in accordance with the following schedule: 147,362 shares on the fifteenth day of the eighteenth month following the closing of the Issuer's initial public offering (the "Tranche 1 Vesting Date"); 147,362 of which will vest nine months after the Tranche 1 Vesting Date (the "Tranche 2 Vesting Date"), and 147,806 of which will vest nine months after the Tranche 2 Vesting Date. Read SEC document |
| May 12, 2022 Filed May 31, 2024 22:26 UTC |
Fortress Biotech, Inc.10% owner
|
OtherCOMMON STOCK, PAR VALUE $0.0001 | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-067324 · tm2416203-2_4seq1.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,060,467 F1 · shares: Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer. Read SEC document |
| January 14, 2022 Filed Apr 4, 2022 20:48 UTC |
Smith Justin AdamDirector
|
GrantCOMMON STOCK | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042279 · tm2211324-9_4.xml · nonDerivative · entry 1 Smith Justin Adam · CIK 0001894583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The 30,000 restricted stock units relating to this grant will vest in three increments as follows: (1) 10,000 units on July 1, 2022, (2) 10,000 units on July 1, 2023, and (3) 10,000 units on July 1, 2024. F2 · balance_after: Includes restricted stock units, which vest over various time periods as set forth in footnote 1. Read SEC document |
| January 14, 2022 Filed Apr 4, 2022 20:49 UTC |
Toledano Miranda JayneDirector
|
GrantCOMMON STOCK | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042282 · tm2211324-11_4.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The 30,000 restricted stock units relating to this grant will vest in three increments as follows: (1) 10,000 units on July 1, 2022, (2) 10,000 units on July 1, 2023, and (3) 10,000 units on July 1, 2024. F2 · balance_after: Includes restricted stock units, which vest over various time periods as set forth in footnote 1. Read SEC document |
| January 14, 2022 Filed Apr 4, 2022 20:51 UTC |
Herskowitz NeilDirector
|
GrantCOMMON STOCK | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042276 · tm2211324-8_4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The 30,000 restricted stock units relating to this grant will vest in three increments as follows: (1) 10,000 units on July 1, 2022, (2) 10,000 units on July 1, 2023, and (3) 10,000 units on July 1, 2024. F2 · balance_after: Includes restricted stock units, which vest over various time periods as set forth in footnote 1. Read SEC document |
| January 14, 2022 Filed Apr 4, 2022 16:47 UTC |
De Paolantonio Ernest RobertChief Financial Officer
|
GrantCOMMON STOCK | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042272 · tm2211324-7_4.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 F1 · shares: The 120,000 restricted stock units relating to this grant will vest in three increments as follows: (1) 40,000 units on October 1, 2022, (2) 40,000 units on October 1, 2023, and (3) 40,000 units on October 1, 2024. F2 · balance_after: Includes restricted stock units, which vest over various time periods as set forth in footnote 1. Read SEC document |
| January 14, 2022 Filed Apr 4, 2022 16:49 UTC |
Paley JeffreyDirector
|
GrantCOMMON STOCK | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042280 · tm2211324-10_4.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The 30,000 restricted stock units relating to this grant will vest in three increments as follows: (1) 10,000 units on July 1, 2022, (2) 10,000 units on July 1, 2023, and (3) 10,000 units on July 1, 2024. F2 · balance_after: Includes restricted stock units, which vest over various time periods as set forth in footnote 1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.